This review helps pharmacists compare buprenorphine-naloxone and naltrexone outcomes, prepare for expanded methadone access, and use stimulant co-use as a risk-stratification signal during opioid treatment.
All three FDA-approved medications for opioid use disorder are effective, but buprenorphine-naloxone offers a modest edge in overdose prevention, and treatment continuity plus harm reduction matter more than agent choice alone.
Medications for opioid use disorder (MOUD), namely buprenorphine-naloxone, extended-release (XR) naltrexone, and methadone, remain the standard of care, with all three considered efficacious under current federal guidance. The practical questions have shifted from whether to treat toward which agent, how to protect continuity, and how to layer harm reduction onto ongoing polysubstance risk.
A large JAMA Network Open target trial emulation now provides the most rigorous comparative data to date, showing buprenorphine-naloxone reduced 24-week nonfatal opioid overdose by 2.3 percentage points versus XR naltrexone with no mortality difference. In parallel, a North Carolina survey characterizes pharmacist readiness for community methadone dispensing ahead of pending legislation, and a PLOS One cohort reframes stimulant use as a time-specific marker of concurrent high-risk behavior during MOUD.
The comparative overdose data align with Substance Abuse and Mental Health Services Administration (SAMHSA) Treatment Improvement Protocol (TIP) 63 and add population-level nuance to the X:BOT trial without displacing the consensus that all three agents work. The stimulant findings reinforce SAMHSA and American Society of Addiction Medicine (ASAM) guidance to retain patients on MOUD despite ongoing non-opioid use and to integrate contingency management, while no US guideline yet addresses community pharmacy methadone dispensing because it remains federally confined to Opioid Treatment Programs (OTPs).
| Source | Key finding | Grade / Verdict |
|---|---|---|
|
Buprenorphine-Naloxone Cuts Nonfatal Overdose vs XR Naltrexone Post-Withdrawal
Study · JAMA network open
new comparative pillar evidence The largest rigorous comparison to date favors buprenorphine-naloxone for overdose prevention while confirming no mortality difference at 24 weeks.
|
Buprenorphine-naloxone cut 24-week nonfatal opioid overdose by 2.3 pp (95% CI 1.2–3.6) vs XR naltrexone, with identical 1.4% mortality | Grade: Moderate Confirmatory |
|
North Carolina Pharmacists Ambivalent but Willing on Methadone Dispensing
Study · Journal of addiction medicine
real-world uptake and readiness gap Community pharmacists are cautiously willing to dispense take-home methadone if legalized, with independent pharmacies and owners most receptive.
|
71.7% of surveyed pharmacists would dispense take-home methadone weekly, but roughly 28% did not want to administer it at all | Grade: Low Hypothesis-generating |
|
Stimulant Use Signals High-Risk Behaviors During Opioid Treatment
Study · PloS one
risk-stratification signal Stimulant use is a time-specific marker of concurrent high-risk behavior during MOUD and a prompt to intensify harm reduction, not to withhold treatment.
|
Stimulant use during treatment roughly tripled the odds of concurrent heroin use (aOR 2.97, 95% CI 1.82–4.82) | Grade: Low Hypothesis-generating |
Subscribe to PharmD Signal for the complete practice recommendations on every topic, plus every deep analysis we publish.
Become a Subscriber →